• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助放化疗后精囊黏附于直肠壁:潜在的假阳性诊断陷阱。

Seminal Vesicle Adherent to Rectal Wall Following Neoadjuvant Chemoradiotherapy: A Potential False-Positive Diagnostic Pitfall.

机构信息

Virginia Commonwealth University Health System, Richmond, VA, USA.

出版信息

Int J Surg Pathol. 2020 Jun;28(4):406-409. doi: 10.1177/1066896920903109. Epub 2020 Feb 2.

DOI:10.1177/1066896920903109
PMID:32008384
Abstract

The standard of care for stage T3 and stage T4 rectal adenocarcinomas involves neoadjuvant chemoradiotherapy followed by either low anterior resection or abdominopelvic resection. The presence of residual adenocarcinoma or positive surgical margins provides useful prognostic information and can influence ongoing adjuvant therapy. Although uncommon, mimics of treated adenocarcinoma may be present in the surgical specimen. A high index of suspicion is critical in avoiding potential false-positive pitfalls, and the exclusion of mimics of treated adenocarcinoma is paramount to accurate diagnosis and treatment. Seminal vesicle epithelium has long been a challenge in differentiating prostatic adenocarcinoma from benign epithelium. However, the role of incidental seminal vesiculectomy in rectal resections due to fibrous adhesion to the rectal wall secondary to chemoradiation has not been studied. As the seminal vesicle epithelium can show markedly atypical nuclei with radiation-type effect at baseline, the potential risk of misinterpretation as residual adenocarcinoma is high. In this article, we present 2 case reports of rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy followed by transabdominal resection (low anterior resection or abdominopelvic resection) with incidental seminal vesiculectomies mimicking either residual adenocarcinoma or residual adenocarcinoma at a margin of resection.

摘要

对于 T3 期和 T4 期直肠腺癌,标准治疗方法包括新辅助放化疗,随后进行低位前切除术或腹会阴切除术。残留腺癌或阳性手术切缘提供了有用的预后信息,并可能影响正在进行的辅助治疗。尽管不常见,但治疗后的腺癌的模拟物可能存在于手术标本中。高度怀疑是避免潜在假阳性陷阱的关键,排除治疗后的腺癌的模拟物对于准确的诊断和治疗至关重要。精囊上皮一直是区分前列腺腺癌和良性上皮的一个挑战。然而,由于化学放射治疗导致直肠壁纤维粘连,偶然进行精囊切除术在直肠切除术中的作用尚未得到研究。由于精囊上皮在基线时可能显示出明显的非典型核,具有放射型效应,因此将其误诊为残留腺癌的风险很高。在本文中,我们报告了 2 例接受新辅助放化疗后行经腹切除术(低位前切除术或腹会阴切除术)的直肠腺癌病例,术中偶然进行了精囊切除术,模拟了残留腺癌或切缘残留腺癌。

相似文献

1
Seminal Vesicle Adherent to Rectal Wall Following Neoadjuvant Chemoradiotherapy: A Potential False-Positive Diagnostic Pitfall.新辅助放化疗后精囊黏附于直肠壁:潜在的假阳性诊断陷阱。
Int J Surg Pathol. 2020 Jun;28(4):406-409. doi: 10.1177/1066896920903109. Epub 2020 Feb 2.
2
Limited Role for Routine Restaging After Neoadjuvant Therapy in Locally Advanced Rectal Cancer.新辅助治疗后局部晚期直肠癌常规再分期的作用有限。
J Surg Res. 2020 Dec;256:317-327. doi: 10.1016/j.jss.2020.06.050. Epub 2020 Jul 23.
3
Clinical Outcomes in T4 and/or N2 Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: A Retrospective Study.新辅助放化疗治疗 T4 和/或 N2 直肠癌的临床结果:一项回顾性研究。
Clin Colorectal Cancer. 2024 Sep;23(3):251-257. doi: 10.1016/j.clcc.2024.04.005. Epub 2024 May 22.
4
Long-term Oncologic Outcomes After Neoadjuvant Chemoradiation Followed by Intersphincteric Resection With Coloanal Anastomosis for Locally Advanced Low Rectal Cancer.局部晚期低位直肠癌新辅助放化疗后经肛门内括约肌间切除术行结肠肛管吻合术的长期肿瘤学结果。
Dis Colon Rectum. 2019 Apr;62(4):408-416. doi: 10.1097/DCR.0000000000001321.
5
Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma.短程放疗和化疗治疗直肠腺癌患者的病理反应和术后并发症。
Clin Colorectal Cancer. 2020 Jun;19(2):116-122. doi: 10.1016/j.clcc.2020.02.005. Epub 2020 Feb 8.
6
Neoadjuvant chemoradiation followed by transanal local excision for T2 rectal cancer confers equivalent survival benefit as traditional transabdominal resection.新辅助放化疗后经肛门局部切除 T2 期直肠癌与传统经腹切除术的生存获益相当。
Surgery. 2019 Jun;165(6):1193-1198. doi: 10.1016/j.surg.2019.02.005. Epub 2019 Mar 21.
7
The role of tissue diagnosis prior to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.组织诊断在局部晚期直肠癌新辅助放化疗前的作用。
Colorectal Dis. 2014 Oct;16(10):783-7. doi: 10.1111/codi.12653.
8
Role of dynamic perfusion magnetic resonance imaging in patients with local advanced rectal cancer.动态灌注磁共振成像在局部进展期直肠癌患者中的作用。
World J Gastroenterol. 2020 May 28;26(20):2657-2668. doi: 10.3748/wjg.v26.i20.2657.
9
Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.使用新辅助放化疗和局部切除对临床T2N0期低位直肠癌进行器官保留(ACOSOG Z6041):一项开放标签、单臂、多机构的2期试验结果
Lancet Oncol. 2015 Nov;16(15):1537-1546. doi: 10.1016/S1470-2045(15)00215-6. Epub 2015 Oct 22.
10
The effect of adjuvant chemotherapy on survival and recurrence after curative rectal cancer surgery in patients who are histologically node negative after neoadjuvant chemoradiotherapy.新辅助放化疗后病理淋巴结阴性的直肠癌患者根治性手术后辅助化疗对生存和复发的影响。
Colorectal Dis. 2017 Nov;19(11):980-986. doi: 10.1111/codi.13714.